Serology study of healthcare workers following a hospital-based outbreak of COVID-19 in North West Tasmania, Australia, 2020
DOI:
https://doi.org/10.33321/cdi.2023.47.6Keywords:
COVID-19, seroprevalence, healthcare workers, hospital-based outbreakAbstract
Introduction
Healthcare facilities are high-risk settings for coronavirus disease 2019 (COVID-19) transmission. Early in the COVID-19 pandemic, the first large healthcare-associated outbreak within Australia occurred in Tasmania. Several operational research studies were conducted amongst workers from the implicated hospital campus, to learn more about COVID-19 transmission.
Methods
Healthcare workers (HCWs) from the implicated hospital campus were invited to complete an online survey and participate in a serology study. Blood samples for serological testing were collected at approximately 12 weeks (round one) and eight months (round two) after the outbreak. A descriptive analysis was conducted of participant characteristics, serology results, and longevity of antibodies.
Results
There were 261 HCWs in round one, of whom 44 (17%) were polymerase chain reaction (PCR) confirmed outbreak cases; 129 of the 261 (49%) participated in round two, of whom 34 (27%) were outbreak cases. The prevalence of positive antibodies at round one was 15% (n = 38) and at round two was 12% (n = 15). There were 15 participants (12%) who were seropositive in both rounds, with a further 9% (n = 12) of round two participants having equivocal results after previously being seropositive. Six HCWs not identified as cases during the outbreak were seropositive in round one, with three still seropositive in round two. Of those who participated in both rounds, 68% (n = 88) were seronegative at both time points.
Discussion
Our findings demonstrate that serological testing after this large healthcare-associated COVID-19 outbreak complemented the findings of earlier diagnostic testing, with evidence of additional infections to those diagnosed when use of PCR testing had been restricted. The results also provide evidence of persisting SARS-CoV-2 antibody response eight months after an outbreak in an unvaccinated population. The high proportion of HCWs who remained seronegative is consistent with low community transmission in Tasmania after this outbreak.
Downloads
References
Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5(9):e475–83. doi: https://doi.org/10.1016/S2468-2667(20)30164-X.
Bielicki JA, Duval X, Gobat N, Goossens H, Koopmans M, Tacconelli E et al. Monitoring approaches for health-care workers during the COVID-19 pandemic. Lancet Infect Dis. 2020;20(10):e261–7. doi: https://doi.org/10.1016/S1473-3099(20)30458-8.
Johnston FH, Anderson T, Harlock M, Castree N, Parry L, Marfori T et al. Lessons learnt from the first large outbreak of COVID-19 in health-care settings in Tasmania, Australia. Western Pac Surveill Response J. 2021;12(4):1–7. doi: https://doi.org/10.5365/wpsar.2021.12.4.884.
Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390–400. doi: https://doi.org/10.1016/S1473-3099(20)30634-4.
Escribano P, Álvarez-Uría A, Alonso R, Catalán P, Alcalá L, Muñoz P et al. Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19. Sci Rep. 2020;10(1):19893. doi: https://doi.org/10.1038/s41598-020-76914-5.
Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S et al. Antibody tests for identification of current and past infection with SARS‐CoV‐2. Cochrane Database Syst Rev. 2020;6(6):CD013652. doi: https://doi.org/10.1002/14651858.CD013652.
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi: https://doi.org/10.1126/science.abf4063.
Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021;32:100734. doi: https://doi.org/10.1016/j.eclinm.2021.100734.
Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240. doi: https://doi.org/10.1126/sciimmunol.abe0240.
Vette KM, Machalek DA, Gidding HF, Nicholson S, O’Sullivan MVN, Carlin JB et al. Seroprevalence of severe acute respiratory syndrome coronavirus 2-specific antibodies in Australia after the first epidemic wave in 2020: a national survey. Open Forum Infect Dis. 2022;9(3):ofac002. doi: https://doi.org/10.1093/ofid/ofac002.
Vaselli NM, Hungerford D, Shenton B, Khashkhusha A, Cunliffe NA, French N. The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: a systematic review. PLoS One. 2021;16(11):e0250541. doi: https://doi.org/10.1371/journal.pone.0250541.
Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM et al. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. 2021;190(1):161–75. doi: https://doi.org/10.1093/aje/kwaa191.
Kayı İ, Madran B, Keske Ş, Karanfil Ö, Arribas JR, Psheniсhnaya N et al. The seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of vaccination: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(9):1242–9. doi: https://doi.org/10.1016/j.cmi.2021.05.036.
Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021; 108:120–34. doi: https://doi.org/10.1016/j.jhin.2020.11.008.
Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Mendez Batres A et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: a cross-sectional analysis during the COVID-19 pandemic. Int J Infect Dis. 2021;102:63–9. doi: https://doi.org/10.1016/j.ijid.2020.10.036.
Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516. doi: https://doi.org/10.1136/bmj.m2516.
Macedo ACL, Prestes GDS, Colonetti T, Candido ACR, Uggioni MLR, Gomes AC et al. A systematic review and meta-analysis of the accuracy of SARS-COV-2 IGM and IGG tests in individuals with COVID-19. J Clin Virol. 2022;148:105121. doi: https://doi.org/10.1016/j.jcv.2022.105121.
Choe PG, Kang CK, Suh HJ, Jung J, Song KH, Bang JH et al. Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection. Emerg Infect Dis. 2021;27(1):327–9. doi: https://doi.org/10.3201/eid2701.203515.
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. 2020;71(10):2688–94. doi: https://doi.org/10.1093/cid/ciaa721.
Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020;173(2):120–36. doi: https://doi.org/10.7326/M20-1632.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–44. doi: https://doi.org/10.1038/s41586-021-03207-w.
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598–607. doi: https://doi.org/10.1038/s41564-020-00813-8.
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–30. doi: https://doi.org/10.1126/science.abd7728.
Stephens N, McPherson M, Cooley L, Vanhaeften R, Wilmot M, Lane C et al. COVID-19: integrating genomic and epidemiological data to inform public health interventions and policy in Tasmania, Australia. Western Pac Surveill Response J. 2021;12(4):1–9. doi: https://doi.org/10.5365/wpsar.2021.12.4.878.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
